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Abstract 
 
Background: The literature on fever related arrhythmic events (AE) in Brugada syndrome (BrS) 
is currently limited to few case reports and small series.  
Objective: The current study aims to describe the characteristics of fever-related AE in a large 
cohort of BrS patients.  
Methods: SABRUS is a multicenter study on 678 BrS patients with first AE documented at time 
of aborted cardiac arrest (ACA) (n=426) or after prophylactic ICD implantation (n=252).  
Results: In 35(6%) of the 588 patients with available information, the AE occurred during a 
febrile illness. Most of the 35 patients were male (80%), Caucasian (83%) and proband (70%). 
Age at time of AE was 29±24 (range 0.3-76) years. Most patients (80%) presented with ACA 
and 6 (17%) with arrhythmic storm. Family history of sudden death, history of syncope and 
spontaneous type 1 Brugada-ECG were noted in 17%, 40% and 66% of patients, respectively. 
VF was induced at EPS in 9/19(47%) patients. An SCN5A mutation was found in 14/28(50%) 
patients. The highest proportion of fever-related AE was observed in the pediatric population 
(age <16), with disproportionally higher event rate in the very young (0-5 years old) (65%). 
Males were involved in all age groups and females only in the pediatric and elderly groups. 
Fever-related AE affected 17 Caucasians aged<24 years, but no Asians aged <24 years.    
Conclusions: The risk of fever-related AE in BrS markedly varies according to age group, 
gender and ethnicity. Taking these factors into account could help the clinical management of 
BrS patients with fever.  
 
Key words: Fever, Brugada syndrome, children, elderly, gender, ethnicity 
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Introduction 
Brugada syndrome (BrS) is an inherited disease that predisposes to sudden cardiac death (SCD), 
mainly affecting males aged 27-59 years old1. Several factors are known to precipitate an 
arrhythmic event (AE) in BrS  patients such as  specific drugs2, increase in vagal tone3 and 
fever4. 
The SCN5A-encoded α-subunit of the NaV1.5 cardiac sodium channel has been linked to BrS 
and mutations in SCN5A are identified in 14–26% of BrS cases5. Dumaine et al.6 were the first to 
link temperature with the function of a mutant SCN5A sodium channel. Later it was 
demonstrated that fever may induce type 1 ECG in BrS patients7. Two large studies 
demonstrated that in unselected populations with fever, type 1 Brugada-ECG may be seen in 2-
4% of patients8,9 and Mizusawa and colleagues10 recently demonstrated that patients who have 
fever-induced type 1 ECG (F-type 1) have an increased risk for syncope and VF. However, there 
are only few case reports and small series describing patients with BrS and proven fever-related 
AE. The Survey on Arrhythmic events in BRUgada Syndrome (SABRUS) is a multicenter study 
that collected data on the first AE in 678 patients with BrS1. The objective of the present study 
was to describe the characteristics of patients with fever-related AE in this large SABRUS 
patient cohort.  
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Methods 
The study was approved by the Tel Aviv Medical Center Institutional Review Board committee. 
The SABRUS patients originated from 23 centers in 10 Western and 4 Asian countries1. Sixteen 
(69.5%) centers provided data from their institution only, whereas the remaining 7 (31.5%) 
provided data from multiple institutions from their countries. 
Data acquisition. Study inclusion criteria consisted of 1) a typical type 1 Brugada-ECG either 
spontaneously (i.e. unrelated to drugs or fever) or following the intravenous administration of a 
cardiac sodium channel blocking drug; 2) a first documented AE (sustained ventricular 
tachyarrhythmia). The detailed information collected on each patient included whether or not the AE 
was associated with fever (oral temperature ≥ 380c or an axillary temperature ≥370c). Other collected 
variables were previously described1   
Definitions.   
- Group A: Patients with documented aborted CA in whom the BrS-diagnosis was made during work-
up performed after CA; Group B: Patients with a BrS-diagnosis in whom prophylactic ICD 
implantation was performed for any reason and in whom an AE requiring appropriate ICD shock 
therapy was documented during follow-up by ICD interrogation.    
Proband status: Proband was defined as the first patient of a family who has been diagnosed with the 
type-1 Brugada-ECG (spontaneous or drug-induced). A non-proband was defined as a family member 
of a known BrS-patient.   
Genetic analysis: When a SCN5A mutation was identified it was classified by its known 
pathogenicity.          
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Age groups: For analyzing the effect of age on fever-related AE, patients were divided into 8 
age categories: 1) early childhood: 0-5 years; 2) late childhood: 6-15 years; 3) adult life: 16-70 
years, divided in 5 equal bins of 11 years; 4) elderly: age>70 years old. 
Model for predicting the risk of AE per day of fever. In order to predict the risk of AE per day of 
fever (day at risk) in each age group a model which took in account the data provided by all 23 main 
centers participating in SABRUS was built. These centers were invited to participate in a registry by 
providing the age and gender distribution of the entire BrS population followed at their own center 
(with or without prior AE). The centers from Western and Asian countries were assumed to include 
Caucasian and Asian patients, respectively, based on SABRUS results.1    
The Delphi method 11 was used in order to estimate the average number of fever days per year in 
the 8-different age groups (described in the supplemental data).  
Statistical analysis. 
Assumptions of normality of the different ages were assessed by Kolmogorov–Smirnov test and Q-Q 
plots. Differences between non-normally distributed ages were assessed using a Mann–Whitney U 
test. Ratio differences were examined by a Chi-square test or a Fisher's exact test as appropriate. 
Statistical significance was defined as P<0.05. Scale variables are presented as Median [IQR] for 
when not normally distributed. All calculations were performed using SPSS version 24 (IBM, 
Armonk, NY, USA).  
Results 
Study patient cohort.  
In 588 (86.7%) of the 678 SABRUS patients, there was information available on a possible 
relationship between AE and fever. In 35 (5.95%) of these 588 patients, the AE occurred during 
a febrile illness. These 35 patients comprised the study group.  
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Characteristics of patients with fever-related AE (Supplemental Table 1). 
The vast majority (n=32) of study patients were provided from the main SABRUS centers while 
only 3 were from subsidiary medical centers.  
Most patients were male (28 of 35, 80%) and Caucasian (29 of 35, 83%) with a mean age of 
29±24 (range 0.3-76) years at the time of AE. The vast majority (28 of 35, 80%) presented with 
aborted CA (group A). Six (17%) patients presented with VF storm. Most patients were probands 
(70%). A family history of SCD and a history of syncope were noted in 17% and 40% of 
patients, respectively.  A spontaneous type 1 Brugada-ECG was observed in 24 (66%) of 
patients. VF was induced at EPS in 9 (47%) of the 19 patients who underwent the procedure. An 
SCN5A mutation was found in 14 (50%) of the 28 patients who underwent genetic testing. In 12 
of them the SCN5A mutations were identified as pathogenic (n=6, 50%) and likely pathogenic 
(n=4, 33.3%) while 2 (16.7%) were classified as a “variant of unknown significance”. In the 
remaining 2 patients information regarding mutation pathogenicity was not available. 
Comparison between patients with or without fever-related AE. 
Age distribution was markedly different in the 2 patient groups (Fig. 1A). In the study group, 13 
(37.1%) of the 35 AE occurred in the pediatric population (age <16 years) particularly in the 
very young (<5 years) (11 of 13, 84.6%); the AE occurred between ages 16-70 in 20 (57.1%) 
patients and after age 70 in 2 (5.7%) patients (Fig. 1A). In contrast, in the patients with AE not 
related to fever, the AE mainly occurred (96%) between 16-70 years and rarely in the pediatric 
and elderly age groups (2.9% and 1.1%), respectively, (P< 0.001) (Fig. 1A).  The highest AE rate 
was observed during early childhood (age 0-5, 65%), followed by a marked decline during late 
childhood (age 6-15, 16.7%) and adulthood (age 16-70, 3.6%) with a subsequent marked rise to 
25% in the elderly (Fig. 1A).  
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Comparisons between patients with and without fever-related AE are presented in Table 1.  
Patients with fever-related AE had a lower proportion of males (80% vs. 92%, P=0.03) and 
probands (70% vs. 87%, P=0.02). In contrast, they were more likely to be younger at time of AE 
[median age (IQR) of 25 (3-46) vs. 43 (34-52), P<0.001)], to belong to Group A (80% vs. 59%, 
P=0.02), to be Caucasian (83% vs. 56%, P=0.007) and to be SCN5A mutation carriers (50% vs. 
31%, P=0.04). 
Other variables including family history of SCD, history of syncope, positive EPS, spontaneous 
type 1 Brugada-ECG and presentation with an arrhythmic storm were not significantly different 
among the 2 groups.  
Comparison between males and females with fever-related AE (Supplemental Table 2A).  
Females with fever-related AE were younger [(median age (IQR) of 3 (0.4-16) vs. 35.5 (7.25-
46.75), P=0.04]. The age distribution of males and females and the percentage of fever-related 
AE at different age groups are presented in Figure 1B. As shown, all fever-related AE in females 
were censored from early childhood until age of 16 with no other cases during adulthood except 
for a single 70-year old female. In contrast fever-related AE in males occurred in all age groups.  
The rate of fever-related AE tended to be higher in female patients aged<26 years as compared to 
males in the same age group (43% vs. 16.7%, P=0.065). Another difference between males and 
females concerned the EPS response. An inducible arrhythmia was observed in 64% of tested 
males but in none of the females (P=0.03). Other analyzed variables were not gender specific.  
Comparison between children (age<16) and adults (age>16) with fever-related AE 
(Supplemental Table 2B).                                                        
There was a non-significant trend toward a higher percentage of females (38% vs. 9%, P=0.08) 
and Caucasians (100% vs. 73%, P=0.06) among children with fever-related AE as compared to 
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adults. An SCN5A mutation was significantly more frequently observed in children (77% vs. 
27% in adults, P=0.008). Other variables including mode of AE presentation, proband status, 
family history of SCD, history of syncope, spontaneous type 1 Brugada-ECG, inducible 
arrhythmia at EPS and VF storm were not different between children and adults.  
Comparison between Caucasians and Asians with fever-related AE (Supplemental Table 
2C).  
Caucasians tented to be younger than Asians [median age (IQR) of 22 (3-45) vs. 42 (31-61), 
P=0.05]. Among the patients with fever-related AE, there were 17 Caucasians aged<24 years old 
including 11 patients aged<5 years whereas the younger Asian patient was 25 years old. 
Caucasians tended to exhibit a spontaneous type 1 Brugada-ECG (P=0.06). The other variables 
tested were not significantly different in respect to patient ethnicity.   
Percentage of patients with AE per age group and estimation of arrhythmic risk for 1000 
fever days. 
Twenty-two of the 23 main SABRUS centers provided the age and gender distribution of the 
entire BrS population followed at their own center (with or without prior AE). The registry 
comprised 6441 patients (73.4% males, 88% Caucasians) including 500 patients with and 5941 
without AE. Of note, the other 178 SABRUS patients who were not followed by the main 
participating centers and in whom the denominator from which these patients were collected was 
unknown, were not included in the present sub-analysis. In 77 of the 500 SABRUS patients, 
there was no information available about the possible association of fever with AE and therefore 
these 77 patients were also excluded from further analysis. A flowchart describing patient 
selection is presented in Figure 2. As shown, overall 32 patients had fever-related AE and 6332 
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patients did not have fever-related AE (including 5941 patients without AE and 391 patients with 
AE not related to fever).   
The age-group distribution of the patients with and without fever-related AE is presented in 
supplemental table 3, demonstrating that 70.9% of the BrS population were 27-59 years old. This 
table also denotes the estimated yearly fever days from the Delphi method.  
The supplemental figure demonstrates the percentages of patients with fever related AE in each 
age group out of the total BrS population (i.e. including also patients without and arrhythmic 
event) that were followed by the main participating centers. As shown a disproportionally high 
percentage of events is seen in age group 0-5 compared to all other age groups.  
Figure 3 demonstrates the estimated AE rate per 1000 fever days according to the specific age 
group. It shows an estimated rate of 14.8 AE (95% CI 7.4, 26.3) per 1000 fever days in BrS 
patients aged 0-5 years old with similar rates between females and males. In contrast, the 
estimated AE rate dropped to 0.33-2.5 events per 1000 fever days in all other age groups.  
Discussion 
Main findings.  
The present study describes the largest series ever reported of BrS patients with fever-related 
AE.  It shows that ≈6% of AE in BrS were associated with fever. These AE mainly occurred in 
Caucasians males, in all age groups and often with a presentation of aborted CA.  The highest 
proportion of fever-related AE was observed in the pediatric population (age<16), with 
disproportionally higher event rate in the very young (0-5 years old). Marked gender differences 
were noted with involvement of males in all age groups contrasting with exclusive female 
involvement in the pediatric and elderly groups. Fever-related AE did not involve any Asian 
patient aged<25 years old.  
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Prior reports on fever-related AE. 
Supplemental Table 4 summarizes all previous publications of fever-related AE in BrS 
comprising 40 patients in 22 reports. Only 4 (18%) of the 22 reports included patients (n=9) who 
originated from Asian countries. Careful analysis of these publications, as well as contact with 
the respective authors, enabled us to confirm that up to 15 cases included in SABRUS had been 
already published, however with very limited data that did not include age and gender in most of 
them4, 12, 13. The largest report includes 7 patients12 while 16 (72%) of these 22 publications dealt 
with case reports. Age and gender were provided for 18 (45%) and 23 (57%) patients, 
respectively. Male involvement was observed in all age groups; however, there were 8 females 
with fever induced AE at very young age (<2 years, n=6) or after menopause (>50 years, n=2). 
ECG data was provided on 18 patients (45%) showing spontaneous type 1 Brugada-ECG in 8 
(44%). Thirteen out of 19 tested patients (68%) had SCN5A mutations. EPS was performed in 4 
patients and was positive in all of them. 
Fever induced Brugada ECG pattern. 
 A prevalence of 2-4% of fever induced Brugada pattern (F-type 1) among febrile patients 
referred to the emergency department was reported in 2 studies 8-9. . This estimate, which is 20 
times higher than the known prevalence of BrS in the general population14,15, suggests that fever 
induced Brugada-ECG changes are benign asnone of the patients in these 2 studies developed an 
AE during follow up. However, Mizusawa et al.10 found that among 88 asymptomatic patients at 
baseline who developed F-type 1 Brugada-ECG, 3 (3.4%) developed an AE including 1 which 
was fever-related. The AE event rate in these 88 asymptomatic patients was 0.9%/year i.e. 
similar to the event rate in patients with spontaneous type 1 (0.5-0.8% /year) 10. Thus, Mizusawa 
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et al.10 suggested that the occurrence of F-type 1 is probably a sign of poorer prognosis, yet it by 
no means implies that the risk for AE is present only or mainly during fever. 
Gender and fever-related AE.  
In the total SABRUS population of 678 patients with AE, females accounted for 8.7% of the 
cohort1. In the present study, however, females involved 20% of the population which exhibited 
fever-related AE.  
One possible explanation for this apparent higher propensity of females to develop fever-related 
AE deals with the higher SCN5A mutation rate observed in patients with fever-related AE (50% 
vs. 31% in those without fever-related) (Table 1), especially in females (80% vs. 43% in males) 
(Supplemental Table 2A).  In this scenario, one could hypothesize on a more proarrhythmic 
effect of fever in mutation carriers.  
Another interesting finding of our study was the exclusive occurrence of AE in females at 
childhood or the elderly while this occurred at all age groups in males. This was also observed by 
others (see Supplemental Table 4) and suggests an “antiarrhythmic protection” in females during 
their reproductive period. Several theories were raised regarding the protective role of female 
gender on disease manifestation including: gender differences in ionic currents16 and the effect of 
sex hormones17. Thus, one may speculate that estrogen and not the absence of testosterone is the 
main protector against fever-related AE in females during their reproductive period.  
Children and fever-related AE. 
Children (age<16 years) represented a considerable proportion of patients with fever-related AE 
(37.1%) despite they comprised only 4.3% the total SABRUS population1. We found that 
children of both genders exhibited a considerable risk of fever-related AE as compared with 
patients in all other age groups. AE were related with fever in 65% and 16.7% of patients aged 0-
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5 and 6-15, respectively, while this was the case in only 3.9% of those patients aged >16 years. 
Previous studies 18,19 suggested a higher risk of fever-related symptoms in children; however 
most described episodes of syncope and not a proven AE.19,20 As children have more febrile 
illnesses compared to adults it was speculated that a greater risk exposure may lead to this high 
rate of fever-related symptoms19. However, when taking into account both total BrS population 
and the average yearly fever days in each age group we found that the risk of AE in a 
comparable risk exposure (i.e. 1000 fever days) is much higher only among children aged 0-5 
years compared to any other group. On the other hand, the higher event rate in children aged 6-
15 may be related to more fever days with similar event rate per 1000 fever days as adults. The 
exact mechanism of this cluster of events in ages 0-5 is unknown and should be further 
investigated. Nevertheless, it has clinical implications as discussed below.  
Another interesting finding of the present study was the higher rate of SCN5A mutation in 
children with fever-induced AE (77%) as compared to adults (27%) (P=0.02). The significance 
of this very high mutation rate should be interpreted with caution since our study was not 
powered to determine whether BrS children without SCN5A mutation have lower risk of AE 
during fever. Nevertheless, significantly lower mutation rates (59 of 201, 29.4%, P=0.001) were 
found in children without previous documented AE aged <16 years (Andorin and Probst, 
Sarquella-Brugada, Giustetto and Conte, personal communication, 2017). Therefore, it is 
possible that the presence of SCN5A mutation in children may indicate a higher arrhythmic risk 
during fever.   
Ethnicity and fever-related AE.  
There were 2 main differences between Caucasians and Asians with regard to fever-related AE. 
First, Caucasians predominated much more in the fever-related AE group than in the afebrile-
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related AE group. Secondly, Asians with fever-related AE were much older and the youngest in 
our cohort was 25 years old. A review of the literature (Supplemental Table 4) confirms the 
extreme rarity of the involvement of Asians in fever-related AE, especially in children, with a 
single report of rapid monomorphic VT in a 2.2 year-old Korean child21. The lower risk for 
fever-related AE in Asian children may suggest that their mutation is sensitive to testosterone, 
which absence during childhood may also protect from the effect of fever. Further research is 
needed to explore this possibility.  
Clinical implications. 
Our results demonstrate that fever-related AE is the first manifestation of the disease in the 
majority of patients and may occur in a substantial number of previously asymptomatic patients 
without spontaneous type 1 Brugada-ECG. Therefore, in accordance with the current 
guidelines22, aggressive antipyretic therapy should be administered to any BrS patient with fever. 
In addition, special attention should be given to those children (especially those aged 0-5 years) 
with syncope and/or febrile seizures who should undergo ECG to exclude the possibility of 
transient BrS-related AE23.  A survey conducted among pediatric electrophysiologists found that 
only 3% of them recommend admission for observation of BrS children with fever.24 Our 
findings suggest that a policy of lower threshold for in-hospital observation should be adopted in 
children, especially in Caucasians aged < 5 years. However, based on our present study and prior 
reports, the risk of AE of any type (fever-related or not) in Asian children seems to be extremely 
low allowing to recommend a more liberal hospitalization policy. Moreover, our data suggest 
that the presence of SCN5A mutation in children may indicate a higher arrhythmic risk during 
fever.  Finally, BrS females at their reproductive age also have a very low AE risk and can be 
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managed conservatively with antipyretics at outpatient settings, unless any alarming symptoms 
occur.  
Limitations. 
In 13.3% subjects from SABRUS there was no information available regarding the occurrence of 
fever during the AE, therefore we cannot exclude the possibility of selection bias.  Not all 
SABRUS patients were followed by the participating centers and the denominator from which 
these patients were collected was unknown. Yet, even if these 178 patients had been excluded 
the results demonstrated in Table 1 and Supplemental Tables 2 would not change meaningfully 
(Supplemental tables 5-6), thus minimizing the possibility of a bias.  The study is retrospective 
and details regarding whether the patients had type 1 Brugada-ECG changes during fever (F-type 
1) were not available, precluding the analysis of  F-type ECG changes as a risk factor for AE. In 
addition our survey did not collect data on QT interval measurements and the possibility of 
overlap syndrome of long QT and BrS in part of our cohort cannot be excluded. Nevertheless, we 
relied on reports from leading centers in the field. Also, information regarding ablative or 1A 
antiarrhythmic therapy which might have influenced the tendency for fever related AE was not 
collected. Our model of AE event risk per 1000 fever days may not be accurate since it is based 
on a calculated estimation of 10 experts since we do not know the exact risk exposure (fever 
days). Nevertheless, the substantial higher risk of fever related AE in children aged 0-5 is also 
demonstrated by the disproportionally higher percentage of fever related AE in that age group. 
Finally, the number of Asians, females and elderly patients is limited; therefore our results 
regarding these subgroups should be taken with caution and further validated by larger cohorts.  
Also, the current cohort includes only 1 elderly female with fever related AE (while in the 
literature we found 2 more cases), thus we can affirm that the risk of females for fever related 
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AE is very low during their reproductive years, however whether their risk increases after 
menopause needs to be studied further. 
Conclusions 
Around 6% of AE in BrS patients are associated with fever. The risk of fever-related AE in BrS 
markedly varies according to age group, gender and ethnical origin of patients. Taking these 
factors into account may help in the clinical management of BrS patients with fever. 
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Table 1: Comparison between Brugada syndrome patients with arrhythmic event related 
or unrelated to fever. 
        
Fever-related AE  AE not related to fever P value 
  n=35 n= 553   
Male Gender (%) 28 (80) 508 (92) 0.03 
Age, years 
 median (IQR) 25 (3-46) 43 (34-52) <0.001 
range  0.3-76 0.3-84 
Group A (%) 28 (80) 328 (59) 0.02 
Probands (%) 23/33 (70) 441/507 (87) 0.02 
Ethnicity (%) 
 
0.009 
Caucasian 29 (83) 312 (56) 
Asian 6 (17) 203 (37) 
Others 0 (0) 38 (7) 
Family history of SCD (%) 6 (17) 122 (22) 0.34 
Spontaneous type 1 Brugada 
(%) 24 (66) 377 (68) 0.96 
History of syncope (%) 14 (40) 224 (41) 0.95 
Positive EPS (%) 9/19 (47) 210/330 (64) 0.15 
SCN5A mutation (%) 14/28 (50) 118/379 (31) 0.04 
VF storm (%) 6 (17) 44 (8) 0.12 
 
AE=arrhythmic event; SCD=sudden cardiac death; EPS=electrophysiological study; VF=ventricular 
fibrillation, IQR=interquartile range.  
Group A is defined as patients with documented aborted CA in whom the BrS diagnosis was made during 
work-up performed after CA. 
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Figure legends 
Figure 1A:  Patient age distribution. Patients with (left panel) or without (middle panel) fever-
related AE are shown. The percentage of patients with fever-related AE in each age group is 
presented on the right panel. The highest percentage of fever-related AE is observed during 
childhood (0-15 years) with another rise in percentage in the elderly (age >70) 
Figure 1B: Age distribution in males and females. Patients with (left panel) or without (middle 
panel) fever-related AE are shown. The percentage of patients in each gender with fever-related 
AE in each age group is presented on the right panel. Since the only females in age groups 16-26 
and 60-70 were 16 and 70 years old, respectively, there are no cases of females with fever-
related AE between ages 17-69.  
Figure 2: Flowchart. Flowchart describing total BrS patient population and how patients were 
divided into subgroups with and without fever-related AE (see text).   
Figure 3: Estimated arrhythmic event rate per 1000 fever days in each age group. The 
circles represent the estimated rate and the whiskers represent the 95% CI. The estimated risk in 
children aged 0-5 is higher than any other group in both genders. When looking at the estimated 
event rate of all patients (marked in black), there is no overlap of any estimation including its 
95% CI with that of 0-5 years old age group.  
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